Creating value with financially adaptive clinical trials

Nature Reviews Drug Discovery

Volumn 14, Issue 8, 2015, Pages 523-524

  David, Frank S ^a   Bobulsky, Sarah ^b   Schulz, Kraig ^c   Patel, Nitin ^d  

^a Pharmagellan   (United States)

^b ERNST AND YOUNG LLP   (United States)

^c Autonomous Tractor Corporation   (United States)

^d Cytel Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDGET; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; SAMPLE SIZE; SHORT SURVEY; STUDY DESIGN; DRUG INDUSTRY; ECONOMICS; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PROCEDURES; RESEARCH; RISK;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HUMANS; RESEARCH; RESEARCH DESIGN; RISK;

EID: 84938424238     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4682     Document Type: Short Survey

References (0)